New data unveiled by Windtree Therapeutics shows significant promise in heart failure patients who have deteriorated into cardiogenic shock.

Cell and gene therapy is not immune to the personalized medicine trend, and BlueSphere Bio hopes its leading T-cell receptor engineering (TCR) platform, along with its TCX-101 clinical candidate, can ultimately bolster the armamentarium for patients with hematologic malignancies and solid tumors.

BlueSphere Bio, for example, is trying to improve the efficacy of allogeneic stem cell transplant (alloSCT) treatments for patients with hematologic malignancies and solid tumors using its T-cell receptor (TCR) discovery platform. That platform, TCXpress™, identifies TCRs that may be especially efficacious against some of the most challenging types of cancer.

SOTIO, a biotech company based in Prague and Cambridge, MA, focuses on improving CAR-T therapies and stable antibody-drug conjugates (ADCs). In its poster presentation, SOTIO announced preclinical data on its immunocytokine SOT201 and the BOXR CAR-T cell therapy BOXR1030. The company’s focus, however, was on its oral presentation featuring SOT101. 

Today, he’s CEO of Ring Therapeutics, a promising emerging biotech backed by Flagship Pioneering

Biosion Inc. has out-licensed ex-China rights for its anti-Siglec-15 monoclonal antibody BSI-060T and additional preclinical assets with the same target to Pyxis Oncology Inc. for $10 million up front and potential milestone payments of up to $222.5 million, plus single to low double-digit royalties on commercial sales.

Private drug discovery company Cerevance reported positive clinical trial results Thursday for CVN424, an experimental treatment for Parkinson’s disease. The drug was discovered using Cerevance’s NETSseq platform, which holds potential for Parkinson’s treatments as well as many other diseases caused by transcriptional genetic errors.